I'd love to be wrong, but I don't think TA can work with a stock like SPL. If it goes to $2.90, it will be because regular profits have become a certainty and/or there has been significant progress in one or more of our clinical trials. Until then the share price should drift lower. That said, I do expect multiple catalysts for the share price this year and $2.90 or more is definitely possible.
Add to My Watchlist
What is My Watchlist?
